To determine the extent by which Sacituzumab Govitecan is able to penetrate the blood brain barrier and access tumor tissue by testing for free SN-38, SN-38G and total SN-38 concentrations in tumor tissue as well as in CSF (if available) and serum samples.
This is a multicenter, open-label, first-in-human Phase 1 study evaluating the anti-PD-1 antibody TSR-042 in patients with advanced solid tumors who have limited available treatment options as determined by the Investigator. The study will be conducted in 2 parts.
Mailbox Ctrc Regulatory Affairs
Dose escalation stage: To determine the MTD and/or recommended Phase 2 dosage (RP2D) of HMPL-689 in patients with relapsed or refractory lymphoma
Dose expansion stage: To confirm the safety and tolerability of selected HMPL-689 dose in patients with relapsed or refractory lymphoma
To assess the preliminary efficacy of HMPL-689 in patients with relapsed or refractory lymphoma
To assess the safety and tolerability of (1) PEGPH20 in combination with cisplatin (CIS) and
gemcitabine (GEM) (PEGCISGEM), and (2) PEGPH20 in combination with CIS, GEM, and